TO THE EDITOR:In a recent article in Liver Transplantation, Goldaracena et al. reviewed the role of liver transplantation (LT) for perihilar and intrahepatic cholangiocarcinoma (ICC). Interestingly, they suggested that patients with an unresectable tumor confined to the hepatic hilum, such as perihilar cholangiocarcinoma (Klatskin tumor), and patients with cirrhosis with very early stage ICC (single tumor of < 2 cm) are potential candidates who might significantly benefit from LT. Although we agree with the suggestion, as they concluded, further studies regarding inclusion criteria and neoadjuvant and adjuvant therapies are urgent in the era of “Transplant Oncology.”In Eastern countries, viral hepatitis infection is one of the most frequent etiologic factors for the development of ICC, especially hepatitis B virus (HBV). ICCs arising from HBV infection hold approximately a half of all resected ICC cases in China and share common characteristics with hepatocellular carcinoma, including younger age and infrequent lymph node metastasis. In addition, our recent study successfully and precisely predicts recurrence of ICC after hepatic resection by adding the presence of HBV infection as a favorable prognostic factor (C‐index, 0.65; 95% confidence interval, 0.50‐0.64). Furthermore, we would like to point out results from our most recent study that showed surprising overall survival (1‐year, 88.9%; 3‐year, 77.8%; 5‐year, 66.7%) of patients with HBV‐associated ICC who underwent hepatic resection and postoperative transarterial chemoembolization (TACE).Because the study reporting the most favorable outcome that was found in patients with a single tumor of <2 cm (1‐year, 93%; 3‐year, 84%; 5‐year, 65%) from Sapisochin et al. is comparable to patients with ICC arising from HBV infection who underwent hepatic resection and postoperative TACE, future large‐sized clinical trials need to evaluate the role of combined LT and postoperative TACE treatment in patients with ICC arising from HBV infection to potentially expand the inclusion criteria of LT for ICC.Seogsong Jeong, M.D.Meng Sha, M.D.Qiang Xia, M.D., Ph.D.Department of Liver SurgeryRenji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai, ChinaREFERENCESGoldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018;24:294‐303.Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun. Surg Today 2017;47:403‐415.Jeong S, Tong Y, Sha M, Gu J, Xia Q. Hepatitis B virus‐associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:17292‐17300.Jeong S, Cheng Q, Huang L, Wang J, Sha M, Tong Y, et al. Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection. BMC Cancer 2017;17:464.Jeong S, Zheng B, Wang J, Chi J, Tong Y, Xia L, et al. Transarterial chemoembolization: a favorable postoperative management to improve prognosis of hepatitis B virus‐associated intrahepatic cholangiocarcinoma after surgical resection. Int J Biol Sci 2017;13:1234‐1241.Sapisochin G, Facciuto M, Rubbia‐Brandt L, Marti J, Mehta N, Yao FY, et al.; for iCCA International Consortium. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 2016;64:1178‐1188.
Liver Transplantation – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera